In laboratories where all CRCs routinely undergo screening for Lynch Syndrome with MMR IHC, the addition of BRAFV600E mutation specific immunohistochemistry would simply be a matter of performing IHC for 5 rather than 4 markers entailing minimal extra labour or handling costs and would have the added advantage of further triaging molecular testing for Lynch Syndrome in MMRd CRC. The gene discussed is MRC1; the disease is colorectal carcinoma.